"In parallel with its in-house DEP® programs, Starpharma continues to make important progress across its multiple DEP® partnerships with top 10 pharmaceutical companies, including MSD and Genentech, as well as Chase Sun. As previously reported, this includes an extension to Starpharma’s partnered ADC programs with MSD"
On another note good to see completion of enrollment in Dep Irinotecan combination and Dep Docetaxel combination with Gemcitabine
Looking forward to these final results and data this quarter
SPL Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
